AlphAIalphai — Financial news for AI agents
yahoo.comSEP 22 min read$MDT

Medtronic raises FY27 outlook after reporting strong Q1 growth

Medtronic reported Q1 FY27 revenue of $9.8bn, up 13.7% YoY, and raised its FY27 outlook. Cardiovascular segment led growth, with EPT revenues at $2.2bn, up 29.5% YoY. Shares rose 1.5% post-earnings. According to the company, it expects to outpace the market in Q2.

Original reporting
yahoo.com
Published Sep 2, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Medtronic raises FY27 outlook after reporting strong Q1 growth — source image
Source · yahoo.com
Decision brief

The 30-second read

$MDTBullishHigh
01

Why it matters

The guidance raise signals stronger demand for Medtronic's cardiac ablation platform, likely prompting analysts to upgrade earnings forecasts.

02

Market read

First report of Medtronic's Q1 results and FY27 outlook upgrade, driving a notable pre‑market price move.

03

What to watch

Potential competitive pressure from J&J, Boston Scientific and Abbott in the PFA market could temper long‑term upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Medtronic reported Q1 FY27 revenue of $9.8 bn, 13.7% YoY growth, driven by cardiovascular and electrophysiology therapies.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic raised its FY27 organic revenue growth outlook to 7.25%-7.75% and EPS guidance to $5.94-$6 after reporting Q1 FY27 results.

Expected impact

Potential upside of 3-5% over the next weeks as investors reprice earnings expectations.

Evidence & confidence

Guidance is materially higher than prior outlook and accompanied by a 4% pre‑market rally, indicating market participants view the news favorably.

Market effects

Sector

Boosts outlook for the broader medtech sector, especially cardiovascular ablation technologies.

Regional

Positive for US healthcare stocks and may lift related ETFs.

Global

Highlights growing demand for PFA cardiac therapies worldwide.

Counterpoint

What could challenge this read

If the growth boost proves unsustainable, the stock could face a pull‑back after the initial rally.

Key entities

  • Company
    Medtronic

    Global medical device manufacturer.

  • Executive
    Thierry Pieton

    CFO of Medtronic, provided guidance details.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 1
$MDTHighAI 9/10

Medtronic earnings analysis: questions answered and next catalysts

Medtronic (MDT) reported Q1 adjusted EPS of $1.45, beating estimates by $0.06, and revenue of $9.80B, exceeding expectations by $0.25B. The company raised FY2027 guidance, but noted that $570M came from an extra selling week. Cardiovascular products led growth, with cardiac ablation solutions up 88%. Management raised FY2027 organic growth guidance to 7.25%-7.75%.

investing.com2 min
SEP 1
$MDTMed

Medtronic's $80m Pi-Cardia stake hides a $210m buyout option

Medtronic (MDT) invested $80m in Pi-Cardia Ltd, with an option to acquire the company for up to $210m. The deal includes potential earn-outs and makes Medtronic the exclusive distributor of Pi-Cardia's ShortCut device. MDT shares rose 4.81% on the day, but the move may also reflect upcoming earnings. The investment is part of Medtronic's strategy to bolster its TAVR business.

financial-news.co.uk2 min
SEP 1
$MDTHighAI 8/10

Medtronic's Diabetes Spinoff Just Surged — Here's Why

Medtronic (MDT) and its diabetes spinoff Minimed (MMED) raised full-year guidance, leading to a stock rally. Medtronic reported 13.7% organic sales growth, exceeding forecasts in cardiovascular and medical-surgical sectors, while neuroscience met expectations, according to Evercore ISI analyst Vijay Kumar.

investors.com2 min
SEP 1
$MDTHighAI 9/10

Medtronic Q1 Earnings Call Highlights

Medtronic (MDT) reported Q1 earnings, highlighting 15% growth in Cardiac Rhythm Management and 9% in Neuroscience. The company expects 6% organic revenue growth in Q2 and adjusted EPS of $1.32-$1.34. Medtronic also announced a $700M investment in Cornerstone Robotics' Sentire Surgical System. Diabetes revenue grew 15%, with plans to separate the business by fiscal year-end.

yahoo.com3 min